AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00403117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 Mg+ Active Marijuana (3.27% THC)
Description: One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
Study NCT03813797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airseal®
Description: Medical device set to the mode Airseal®, pressure adjustment between 5 and 7 mmHg
Study NCT03813797 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Insufflation
Description: Medical device set to the mode Standard Insufflation, pressure adjustment between 12 and 15 mmHg
Study NCT02448680 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Coagulation FVIIa (Recombinant)
Description: A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
Study NCT02108639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study NCT02195401 — intervention group
Intervention type: OTHER
Intervention: Cleanroom
Description: Cleanroom with air the quality of the pre-industrial age
Study NCT02195544 — intervention group
Intervention type: DRUG
Intervention: Synvisc®
Study NCT01460628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
Study NCT03435640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-262
Description: During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262.~During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262.
Study NCT03435640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bempegaldesleukin
Description: During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.~During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.
Study NCT03435640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
Study NCT00015938 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00015938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00015938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study NCT00570479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anecortave acetate
Description: Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
Study NCT00403117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 Mg+ Active Marijuana (3.27% THC)
Description: One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before marijuana administration.
Study NCT00403117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 12 Mg + Inactive Marijuana (0% THC)
Description: One capsule containing 12mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
Study NCT03163264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Assisted Lifestyle
Description: Patients will use PAL online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
Study NCT00403117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 25 Mg + Inactive Marijuana (0% THC)
Description: One capsule containing 25mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
Study NCT03163264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling.
Study NCT00403117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 Mg + Inactive Marijuana (0% THC)
Description: One capsule containing 50mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
Study NCT00403117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 100 Mg + Inactive Marijuana (0% THC)
Description: One capsule containing 100mg Naltrexone was administered to the participant in a size 00 opaque capsules with lactose filler 45 minutes before inactive marijuana administration.
Study NCT04451642 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral nerve block
Description: Peripheral nerve block consists of the administration of a local anaesthetic into the nerves to inhibit nerve transmission in a specific part of the body. Ultrasound or Nerve stimulator could be used to locate the peripheral nerve. A needle is placed through the anatomical references to administer local anaesthetic around the peripheral nerve. Single-shot or continuous blocks are performed preoperatively and postoperatively as current practice in the surgery theatre. Using ultrasound, in-plane or out-plane approach could be performed. Peripheral nerve block provides excellent intraoperative and postoperative analgesia decreasing the need for intravenous pain drugs. Interscalene block, supraclavicular block, safene block, femoral block, BRILMA block are different kinds of peripheral nerve block using in the anaesthestic current practice.
Study NCT01381887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
Study NCT01381887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg/Placebo
Description: Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods.
Study NCT01381887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg/Canagliflozin 150mg
Description: Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.~Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods.
Study NCT01381887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300mg
Description: Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
Study NCT03032068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: At-Home Monitoring
Description: Patient reported outcomes, functional measures such as the maximum attainable range of motion (AROM) and the number of steps taken will be tracked using sensors worn by the patient. The AROM sensor values will be verified with range of motion measurements taken using a goniometer during therapy and MD visits.
Study NCT01458444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation (VNI)
Description: BIPAP® vision
Study NCT01458444 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non invasive ventilation
Description: OPTIFLOW system
Study NCT02958761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intraarticular injections of platelet lysate
Study NCT02214212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright White Light (BWL)
Description: The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
Study NCT02214212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Red Light (RL)
Description: The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
Study NCT00890656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX)
Description: 300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
Study NCT00890656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg by vein (IV) weekly for 3: Days 1, 8, 15
Study NCT00890656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m\^2 by vein (IV) over 24 hours
Study NCT02958761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
Study NCT00890656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: 80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
Study NCT00890656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
Study NCT00890656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: 200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
Study NCT00890656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: 3 gm/m\^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
Study NCT00890656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
Study NCT01023737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
Study NCT03641885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mothers and adolescents
Description: The intervention package will be sent to mothers and adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
Study NCT03641885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adolescents
Description: The intervention package will be sent to only adolescents via Telegram social media. It contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. There will be 3 assessment points in time, baselines, 1 month and six months after interventions.
Study NCT03641885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active control
Description: The active control group receives an information sheet regarding recommendations on oral health behavior via telegram. There will be 3 assessment points in time, with 1 month and six months in between.
Study NCT04257513 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Neurological and Cognitive evaluation; Brain MRI
Study NCT01097681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral
Study NCT04389632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sigvotatug vedotin
Description: Administered into the vein (IV; intravenously)
Study NCT04389632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg every 3 weeks or 400mg every 6 weeks, given by IV
Study NCT04389632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 every 3 weeks, given by IV
Study NCT04389632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 5 mg/mL per min every 3 weeks, given by IV
Study NCT01150370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The PrePex a novel device for adult male circumcision
Description: The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
Study NCT00674843 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation
Description: Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
Study NCT01444924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Description: The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
Study NCT01444924 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
Study NCT02016599 — intervention group
Intervention type: OTHER
Intervention: Monitoring and biospecimen collection
Description: The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate, troponin, and creatinine levels.
Study NCT04103645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vactosertib
Description: This drug is a TGF-Beta receptor type 1 inhibitor, by inhibiting phosphorylation of the ALK5 substrates SMAD2 and SMAD3. This inhibition could promote regeneration of normal human stem cells and proliferation of erythroid progenitors to treat the underlying hypoproliferative anemia in advanced MPNs.
Study NCT04058756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: PDR001
Study NCT03813290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-technological Intervention
Description: During the intervention sessions, participants will don a head-mounted VR display set and a mobile EEG-biosensor. Each session will begin with a brief audio-guided mindfulness practice, follow by a 15 minutes VR game. Game performances will be influenced by individual's level of anxiety arousal and ability to regulate it.
Study NCT04274218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation
Description: Participants from both cohorts will experience a simulated trip while walking on the treadmill. The trip is induced through a rapid acceleration and deceleration of the treadmill belt speed.
Study NCT03266627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytotoxic t-lymphocytes
Description: adenovirus specific cytotoxic t-lymphocytes will be collected and manufactured from HLA matched related or HLA mis-matched related donors and administered to eligible patients with refractory adenovirus or PID.
Study NCT00642265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osteosynthesis
Description: operative treatment
Study NCT00642265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sling
Description: conservative treatment
Study NCT00306098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: islets
Description: Intraportal infusion of islets
Study NCT00420056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: 125 mg, oral, Days 1-21 of a 28-day cycle
Study NCT01023737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
Study NCT00914017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin, 40 mg daily for 1 year
Study NCT00914017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill daily for 1 year
Study NCT04619680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: 150 mg PO twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
Study NCT04619680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 150 mg equivalent twice a day, taken with food food (or, for Child-Pugh A patients, 100 mg by mouth twice daily).
Study NCT01824082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Perineural infusion [continuous peripheral nerve block(s)]
Description: Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
Study NCT01824082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural infusion [continuous peripheral nerve block(s)]
Description: Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
Study NCT04252703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: Invasive cardiac catheterization, balloon angioplasty and intracoronary stenting.
Study NCT04252703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: Invasive cardiac catheterization, balloon angioplasty and intracoronary stenting.
Study NCT03896399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ischemic conditioning followed by esophagectomy
Description: All included patients will receive a laparoscopic ischemic conditioning followed by an esophagectomy after an interval of 12-18 days.
Study NCT03918642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy
Description: Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
Study NCT03918642 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy
Description: Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
Study NCT04349995 — intervention group
Intervention type: DEVICE
Intervention: Amplatzer PFO Occluder
Description: Percutaneous PFO closure using Amplatzer PFO Occluder
Study NCT05241171 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.
Study NCT05241171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: The study participants in intervention group received feedback based on steps achieved every week (converted to average steps per day) after randomization.